Valuation issues Jan Sørensen, Health Economist CAST – Centre for Applied Health Services Research and Technology Assessment University of Southern Denmark.

Slides:



Advertisements
Similar presentations
Correcting Market Distortions: Shadow Prices, Shadow Wages and Discount Rates Chapter 6.
Advertisements

Com 4FK3 Financial Statement Analysis Week 5, 2012 Fixed Assets.
FOCUS QUESTION 2 WHAT ARE PRIORITY ISSUES FOR IMPROVING AUSTRALIA’S HEALTH?
A Cost-Benefit Analysis of Net Based Nursing Education by Niklas Hanes and Sofia Lundberg, Centre for Regional Science at Umeå University (CERUM), Sweden.
The Perfect Plan… To Rescue Poorly Performing Assets Agent Use.
Chapter 11 Age and Health Inequalities. Chapter Outline  The Structures of Aging and Health Care  Age Differentiation and Inequality  Explanations.
REACH: Impact on Occupational Health Simon Pickvance University of Sheffield.
Toward a Sustainable Future Name of Conference, Event, or Audience Date Presenter’s Name | ©2011 Synapse Energy Economics Inc. All.
Values, cost-benefit analysis and adaptation to climate change Alistair Hunt and Tim Taylor University of Bath, UK Tyndall Conference Living with climate.
Economic Analysis and Management Todd Wagner, PhD.
A METHODOLOGY FOR MEASURING THE COST- UTILITY OF EARLY CHILDHOOD DEVELOPMENTAL INTERVENTIONS Quality of improved life opportunities (QILO)
Economic evaluation considers assessment of intervention effects in economic terms, which is often of greatest interest to fund allocators Intervention.
1 Social Discount Rate Scott Matthews Courses: and Lecture /20/2004.
ENVIRONMENTAL BENEFIT COST ANALYSIS Traditional BCA Decision making without environmental values (too difficult to evaluate, subjective, irrelevant) Modern.
Health Care Organizations
1 Chapter 9 - Insurance Purpose – protect against catastrophes Risk pooling and diversification Policy – a contract with an insurance company –Losses covered,
Trends In Health Care Industry KNH 413. Difficult questions What is health insurance? What is health care versus health insurance? Is one or both a right.
Indicators of health and disease frequency measures
Do we need economics in medicine?. Edmund Burke, 1790 dcist.com/2007/12/10/revisiting_edmu.php “…the age of chivalry is gone. That of sophisters, economists,
Health Economics & Policy 3 rd Edition James W. Henderson Chapter 4 Economic Evaluation in Health Care.
INSURANCE How it works… Why YOU need it…. ALL ABOUT RISK The chance of financial loss from some type of danger RISK MANAGEMENT AVOID THE RISK – Don’t.
Disease Management: High Risk Groups Principles in Practice Copyright © – Academy of Managed Care Pharmacy (AMCP)Slide 1.
OECD Workshop on Measuring Education and Health Volume Output, Paris, 6-7 June 2007 Draft Chapter 1 – Terminology and Concepts Paul Schreyer and François.
Cost-Effectiveness Problem l You have a $1.5 billion budget to spend on any combination of these programs:
Generational Accounting Workshop Nov. 11, 2014 NTA10, Beijing.
ECON 6012 Cost Benefit Analysis Memorial University of Newfoundland
Annuities In Retirement Planning For Joe and June.
African Centre for Statistics United Nations Economic Commission for Africa Handbook on Supply and Use Table: Compilation, Application, and Good Practices.
Measurement Measuring disease and death frequency FETP India.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 4: Measuring costs - Part 1 Sept 15,
Environmental Economics Class 6. Concepts Static efficiency Dynamic efficiency Static efficiency allows us to evaluate those circumstances where time.
Economic evaluation Definition - the comparative analysis of alternative courses of action in terms of both their cost and consequences.
Measuring Efficiency CRJS 4466EA. Introduction It is very important to understand the effectiveness of a program, as we have discovered in all earlier.
HEALTH ACCOUNTS FOR PORTUGAL. Health Accounts for Portugal Project “Health Accounts for Portugal” was carried out for the year 2000 to answer.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 6: Cost-effectiveness analysis – Part.
Basic Economic Analysis David Epstein, Centre for Health Economics, York.
Mohammad Aljawadi PharmD, PhD Clinical Pharmacy Department King Saud University PHCL 431 Sep, 2015.
Cost-Effectiveness and Cost-Benefit Analysis N287E Spring 2006 Joanne Spetz 31 May 2006.
Chapter 7 The Health Care System. Three Models of Health Care: The Medical Model Focus on diagnosis and cure Care in hospital, doctor’s office, nursing.
Chapter 4: Cost-Benefit Analysis Chapter 4 Cost-Benefit Analysis Copyright © 2009 by The McGraw-Hill Companies, Inc. All rights reserved. McGraw-Hill/Irwin.
Human costs of tobacco-related diseases * Marco Vannotti, France Priez, Claude Jeanrenaud, Jean-Pierre Zellweger Institut de recherches économiques et.
PHARMAC What is PHARMAC? PHARMAC - the Pharmaceutical Management AgencyPHARMAC - the Pharmaceutical Management Agency A New Zealand Government Agency (Crown.
Feasibility Study.
Chapter 2 Thinking Like an Economist Ratna K. Shrestha.
AGEC 608 Lecture 01, p. 1 AGEC 608: Lecture 1 Objective: Introduction to main concepts Readings: –Boardman, Chapter 1 –Kankakee, summary of Draft Assessment.
The financial costs and benefits of alcohol The financial costs and benefits of alcohol Christine Godfrey Department of Health Sciences & Centre for Health.
Flagship Program on Health Sector Reform and Sustainable Financing.
Capital Insight Pty Limited ABN Berry Street North Sydney NSW 2060 t f Health Economics.
Cost benefit analysis (COBA) is a technique for assessing the monetary social costs and benefits of a capital investment project over a given time period.
1 Special Topics in Cost-Effectiveness Analysis: Indirect Costs, Discounting Gerald F. Kominski, Ph.D. Professor, UCLA Department of Health Services.
Chapter 2: The Role of Economics
CRJS 4466 PROGRAM & POLICY EVALUATION LECTURE #6 Evaluation projects Questions?
Cash Flow Estimation and Risk Analysis Chapter 12  Relevant Cash Flows  Incorporating Inflation  Types of Risk  Risk Analysis 12-1.
1 Chapter 3: The Measurement Fundamentals of Financial Accounting.
Human resources in health care system in Estonia – opportunities and challenges Pille Saar Ministry of Social Affairs of Estonia.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 7: Cost-effectiveness analysis – Part.
Cost benefit analysis. Social costs Social costs are the costs of economic activity to society as a whole Social costs = private costs + external costs.
Cost effectiveness Analysis: Valuing Health; Valuing Research!
HEALTH ECONOMICS BASICS
EWG Study Tour, Galway, 18/09/2006
HEALTH ACCOUNTS FOR PORTUGAL.
Lecture: 6 Course Code: MBF702
Economic Evaluation of Health Interventions Basic Concepts
Economics and Work Economic Value of a Good: Concept of a Just Price Human Capital Social Capital as a Means to Decrease Economic Deprivations.
A Growing and Ageing Population
Sergio Bautista-Arredondo National Institute of Public Health Mexico
Return to Home Page GEOG 370 May 5,
Social prescribing in County Durham
Lecture was elaborated with the help of grant project of Ministry of Education, Youth and Sports, FRVŠ n „Innovation of Subject Financing of Building.
Presentation Developed for the Academy of Managed Care Pharmacy
Presentation transcript:

Valuation issues Jan Sørensen, Health Economist CAST – Centre for Applied Health Services Research and Technology Assessment University of Southern Denmark

Cost-benefit analysis of future energy plans Assess and compare the cost and benefits of different alternatives from a social perspective Assess and compare the cost and benefits of different alternatives from a social perspective CBA is based on well-established economic theory (welfare economics), which might serves as reference case when in doubt CBA is based on well-established economic theory (welfare economics), which might serves as reference case when in doubt Many reference books Many reference books  International guidelines  Ministry of Finance, Guidelines 1999 Many examples on applications within different other public sectors including the environmental area eg. Møller et al, 2000 Many examples on applications within different other public sectors including the environmental area eg. Møller et al, 2000

Important decisions Social perspective Social perspective  Include all relevant effects and resource use (cost)  Valued from a social perspective Long time horizon Long time horizon  Include long term consequences of the specified energy scenarios for one year e.g. 2010, 2020, 2050)  Analytical (scenario) horizon assumed to be one year  Consider the long term consequences of this year’s energy production Aim to express both the benefits and cost in monetary units (however, should also present intermediate results – eg. new cases of disease, life years lost, additional use of health services) Aim to express both the benefits and cost in monetary units (however, should also present intermediate results – eg. new cases of disease, life years lost, additional use of health services) Provide a transparent, comprehensive and reliable analysis Provide a transparent, comprehensive and reliable analysis In the following: Restricted focus on the cost and benefits relating to the health effects of pollution associated with changes in energy production In the following: Restricted focus on the cost and benefits relating to the health effects of pollution associated with changes in energy production

Additional incidence of diseases – new cases by sex and age Impact on health status: death, time with illness, QALY Additional use of resource: Hospitals, primary care, medicine, social service, voluntary services, time Value of avoided death, time with illness, QALY Productive time Consumption Unit cost per resource Net present value of the benefits Net present value of the resource use (costs) * ~ * ~

Which value ? Economic theory: Economic theory:  The opportunity cost i.e. the utility of the second best application of the resources  Valued from the perspective of society – usually as the aggregation of the values of each individual in the society  Marginal (inkremental) analysis i.e. the cost and benefit of the last unit/difference Difficult to make operational outside a perfect market situation Therefore often approximated as the long term average cost, i.e. variable cost with reasonable contribution to the fixed cost

Example A 55 year old man who becomes ill with a stroke and survive the immediate period A 55 year old man who becomes ill with a stroke and survive the immediate period Additional resource use Additional resource use  Hospital care in the immediate period (e.g. first 1 month)  Rehabilitation period (additional training)  Maintenance period (home improvement, ongoing support, GP and nursing service, medication, meals on wheels etc.) in own home  Admission to nursing home until rest of life time NPV of the additional resource use each year in the remaining life time (x euro per case with a specific age and sex group) NPV of the additional resource use each year in the remaining life time (x euro per case with a specific age and sex group)

Method - Register study Identify population with new disease and suitable controls Identify population with new disease and suitable controls Assess the expected life time with the disease Assess the expected life time with the disease Assess additional resource use (attributable cost= difference between diseased and controls) in each year Assess additional resource use (attributable cost= difference between diseased and controls) in each year  e.g. hospital, primary care and medicine  e.g. valuation through DRG-system, fees paid by primary care funding body, and pharmacy sales prices  NPV (Unit cost) per new case = Σ t qt * pt(q) * δt

Time cost of seeking treatment Patient and relatives Alternative cost Alternative cost  Value of missed employment: missed income (net of tax)  Leisure time: missed leisure time

Valuation of benefit - 1 Avoided death/life years lost/lost time without illness Avoided death/life years lost/lost time without illness  Different valuation methods  Contingent valuation  Discrete choice

Valuation of benefit - 2 Production loss Production loss  Human capital method: lost time => retirement age  Friction cost method: lost time => replaced at labour marked (6 mths)  Valuation: gross salary before tax  Note risk of double counting!

Valuation of benefit - 3 Future consumption (hospital and other resources) Future consumption (hospital and other resources)  People living longer have more consumption eg. food, housing, holidays  Represent a use of social resources  Arise in the gained life time

Deliverables Tables of aggregated NPV net benefit (cost) of new illnesses (defined by the WP3 group) by age and sex groups (as defined by the detailed CEEH model) under different sets of assumptions regarding discount rates Tables of aggregated NPV net benefit (cost) of new illnesses (defined by the WP3 group) by age and sex groups (as defined by the detailed CEEH model) under different sets of assumptions regarding discount rates Documentation of details in deriving such figures Documentation of details in deriving such figures Activities Activities  Register study  Survey of population values (health, life years /QALY gain)  Perhaps survey of population values of environmental consequences

Examples of earlier unit costs Frohn et al, PP-presentation, May 2007